• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » eResearch Income Falls 63%

eResearch Income Falls 63%

July 31, 2009
CenterWatch Staff

Philadelphia-based eResearch Technology (ERT) reported second quarter financial results after the markets closed Thursday. Included in the results were ERT’s electronic data capture (EDC) operations, which were sold to Omnicomm Systems in June.

ERT’s second-quarter revenues were down 32% to $24.2 million, compared to $35.5 million a year ago. EDC licenses and service revenues accounted for $1.1 million of total revenue. The company reported a $500,000 gain on the sale of its EDC operations.

Net income for ERT was also down significantly over last year. Second quarter net income was $2.5 million, or $0.05 per diluted share, compared to $6.7 million, or $0.13 per diluted share a year ago.

 “Revenue and bookings continue to be significantly impacted by lower spending by clients on Thorough QT trials,” ERT president and CEO Michael McKelvey said in a statement. “Sponsors may delay the running of Thorough QT trials until later in the drug development cycle, though regulatory guidance ultimately requires that they be performed. As previously announced, we consolidated our customer care teams in Philadelphia and continue to improve the efficiency of our operations. This resulted in increases in our margins in the second quarter and will positively impact our cost base in the future. We believe the divestiture of our EDC operations will be positive for ERT as it allows us to focus our efforts on cardiac safety and ePRO opportunities."

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing